Therapeutic implications of cancer stem cells.

By M. Al-Hajj, M. Becker, M. Wicha, Irving L. Weissman, M. Clarke. Current Opinion in Genetics and Development, 2004

611 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/2faeeba5a9137162a835c2b68f806262560d2997

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Wicha
2. Linheng Li
3. P. Steeg
4. W. Neaves
5. Piero Dalerba
6. P. Dirks
7. Robert W. Cho
8. M. Clarke

In Oncology

1. M. Wicha
2. P. Steeg
3. G. Dontu
4. Linheng Li
5. W. Neaves
6. M. Clarke
7. Piero Dalerba
8. P. Dirks

Citations in the corpus

• Tumour-initiating cells: challenges and opportunities for anticancer drug discovery (2009, background): “It has been suggested that the more aggressive and refractory cancers contain more tumour-initiating cell”
• Tumor metastasis: mechanistic insights and clinical challenges (2006, background): “The stem cell compartment is of critical importance to metastasis if distinct regulatory pathways are operative as compared to primary tumor cell”
• ALDH1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer (2009, background): “This either suggests that ALDH1 and CD44/CD24 are detecting distinct although overlapping cell populations or that the reliability of detection of CD44/CD24 in fixed tumor tissue may be limited (16, 36).”
• Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity (2008, background): “Whether such a CSC niche really exists and which cells constitute this niche in vivo remains to be established (23), but proving its existence or identification of the signals that regulate CSC proliferation and differentiation could be of vital importance for therapeutic strategies to prevent tumor”
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer (2006, background): “It has becoming increasingly clear that tumour cells are not homogeneous and that cancer stem cells exis”
• Normal stem cells and cancer stem cells: the niche matters. (2006, background): “This circumstance has implications for both therapy and research (11).”
• Cancer stem cells: models and concepts. (2007, background): “Based on this concept, traditional treatments might be recalibrated and investigational therapies developed, focusing on their ability to target the CSC subpopulation and its specific biochemical pathways (89, 90).”
• Tumour stem cells and drug resistance (2005, background): “In the haematopoietic system, there are three different populations of multipotent progenitors — stem cells with a capacity for long-term renewal, stem cells with a capacity for short-term renewal, and multipotent progenitors that cannot renew but differentiate into the varied lineages in the bone m”